Jim Simons Voyager Therapeutics, Inc. Transaction History

Renaissance Technologies LLC

$63.1 Billion
Q3 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Voyager Therapeutics, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 278,667 shares of VYGR stock, worth $1.61 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

278,667

Previous 63,200 340.93%

Holding current value

$1.61 Million

Previous $499,000 226.65%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$5.77 - $9.27 $1.24 Million - $2 Million	215,467 Added 340.93%	278,667 $1.63 Million
Q2 2024 Aug 09, 2024	SELL	$7.42 - $10.54 $481,558 - $684,046	-64,900 Reduced 50.66%	63,200 $499,000
Q1 2024 May 13, 2024	SELL	$7.15 - $10.84 $393,250 - $596,200	-55,000 Reduced 30.04%	128,100 $1.19 Million
Q4 2023 Feb 13, 2024	SELL	$6.28 - $8.81 $1.38 Million - $1.94 Million	-220,500 Reduced 54.63%	183,100 $1.55 Million
Q3 2023 Nov 14, 2023	BUY	$7.55 - $11.25 $684,030 - $1.02 Million	90,600 Added 28.95%	403,600 $3.13 Million
Q2 2023 Aug 11, 2023	BUY	$6.94 - $13.99 $1.25 Million - $2.53 Million	180,700 Added 136.58%	313,000 $3.58 Million
Q1 2023 May 12, 2023	BUY	$6.0 - $10.78 $78,000 - $140,140	13,000 Added 10.9%	132,300 $1.02 Million
Q4 2022 Feb 13, 2023	BUY	$4.94 - $6.61 $12,350 - $16,525	2,500 Added 2.14%	119,300 $728,000
Q3 2022 Nov 14, 2022	BUY	$5.57 - $7.47 $125,325 - $168,075	22,500 Added 23.86%	116,800 $691,000
Q2 2022 Aug 12, 2022	BUY	$4.82 - $10.09 $454,526 - $951,487	94,300 New	94,300 $557,000
Q1 2022 May 13, 2022	SELL	$2.75 - $9.44 $144,696 - $496,704	-52,617 Closed	0 $0
Q4 2021 Feb 11, 2022	SELL	$2.47 - $5.55 $648,399 - $1.46 Million	-262,510 Reduced 83.3%	52,617 $143,000
Q3 2021 Nov 12, 2021	SELL	$2.63 - $4.12 $197,941 - $310,083	-75,263 Reduced 19.28%	315,127 $829,000
Q2 2021 Aug 13, 2021	SELL	$3.94 - $5.44 $137,943 - $190,459	-35,011 Reduced 8.23%	390,390 $1.61 Million
Q1 2021 May 13, 2021	SELL	$4.61 - $9.04 $1.87 Million - $3.66 Million	-404,858 Reduced 48.76%	425,401 $2 Million
Q4 2020 Feb 10, 2021	BUY	$7.15 - $12.28 $29,014 - $49,832	4,058 Added 0.49%	830,259 $5.94 Million
Q3 2020 Nov 13, 2020	SELL	$10.01 - $13.75 $194,984 - $267,836	-19,479 Reduced 2.3%	826,201 $8.82 Million
Q2 2020 Aug 13, 2020	SELL	$8.05 - $14.21 $1.59 Million - $2.8 Million	-197,121 Reduced 18.9%	845,680 $10.7 Million
Q1 2020 May 14, 2020	SELL	$6.8 - $14.66 $1.38 Million - $2.97 Million	-202,700 Reduced 16.27%	1,042,801 $9.54 Million
Q4 2019 Feb 13, 2020	BUY	$12.82 - $16.85 $2.21 Million - $2.91 Million	172,600 Added 16.09%	1,245,501 $17.4 Million
Q3 2019 Nov 13, 2019	BUY	$16.31 - $28.29 $5.6 Million - $9.71 Million	343,100 Added 47.01%	1,072,901 $18.5 Million
Q2 2019 Aug 12, 2019	BUY	$19.18 - $27.88 $4.56 Million - $6.62 Million	237,500 Added 48.24%	729,801 $19.9 Million
Q1 2019 May 14, 2019	BUY	$8.0 - $19.66 $480,000 - $1.18 Million	60,000 Added 13.88%	492,301 $9.42 Million
Q4 2018 Feb 13, 2019	BUY	$8.59 - $18.05 $3.71 Million - $7.8 Million	432,301 New	432,301 $4.06 Million

Others Institutions Holding VYGR

# of Institutions

130

Shares Held

34.7M

Call Options Held

39.7K

Put Options Held

34.6K

View Full List

About Voyager Therapeutics, Inc.

Ticker VYGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,647,600
Market Cap $223M
Description
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyo...

More about VYGR

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account